A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi Arabia

Active, not recruitingOBSERVATIONAL

Enrollment

3,500

Participants

Timeline

Start Date

May 5, 2025

Primary Completion Date

November 28, 2025

Study Completion Date

December 3, 2025

Conditions

Rheumatoid ArthritisPsoriatic Arthritis

Interventions

DRUG

Leflunomide

This study will not administer any treatment, only observe the treatment as prescribed in real-world clinical practices.

Trial Locations (1)

Sanofi-Aventis, Chilly-Mazarin